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Abstract
Background: Recently, rapid advances have been made in metabolomics-based, easy-to-use early cancer detection
methods using blood samples. Among metabolites, profiling of plasma free amino acids (PFAAs) is a promising approach
because PFAAs link all organ systems and have important roles in metabolism. Furthermore, PFAA profiles are known to be
influenced by specific diseases, including cancers. Therefore, the purpose of the present study was to determine the
characteristics of the PFAA profiles in cancer patients and the possibility of using this information for early detection.
Methods and Findings: Plasma samples were collected from approximately 200 patients from multiple institutes, each
diagnosed with one of the following five types of cancer: lung, gastric, colorectal, breast, or prostate cancer. Patients were
compared to gender- and age- matched controls also used in this study. The PFAA levels were measured using high-performance
liquid chromatography (HPLC)–electrospray ionization (ESI)–mass spectrometry (MS). Univariate analysis revealed significant
differences in the PFAA profiles between the controls and the patients with any of the five types of cancer listed above, even
those with asymptomatic early-stage disease. Furthermore, multivariate analysis clearly discriminated the cancer patients from
the controls in terms of the area under the receiver-operator characteristics curve (AUC of ROC .0.75 for each cancer), regardless
of cancer stage. Because this study was designed as case-control study, further investigations, including model construction and
validation using cohorts with larger sample sizes, are necessary to determine the usefulness of PFAA profiling.
Conclusions: Thesefindings suggestthatPFAA profiling hasgreatpotential forimprovingcancerscreeninganddiagnosis and
understanding disease pathogenesis. PFAA profiles can also be used to determine various disease diagnoses from a single
blood sample, which involves a relatively simple plasma assay and imposes a lower physical burden on subjects when
compared to existing screening methods.
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Several minimally-invasive, easy-to-use cancer diagnostic meth-
ods using peripheral blood or urine samples have recently been
developed to ease the physical burden on patients and to reduce
the costs and time involved [1,2,3,4,5,6,7,8]. Rapid advances have
been made in cancer diagnosis and prognosis methods based on
metabolome analysis [3,9,10,11,12,13,14], which frequently
involves the use of multivariate analysis techniques, such as
computer-aided, machine-learning systems for data mining.
Although metabolome analysis is a promising approach in
screening for diseases such as cancer, some practical limitations
remain. These include the necessity to measure a huge number of
metabolites [15,16,17], data-redundancy problems, including the
false-discovery rate (FDR) and overfitting, and cost constraints.
One approach to overcoming these problems is ‘‘focused
metabolomics’’, which limits the objects of the analysis to those
that play roles in general metabolism and share physical
similarities.
Amino acids are among the most suitable candidates for focused
metabolomics as they are either ingested or synthesized endoge-
nously and play essential physiological roles both as basic
metabolites and metabolic regulators. To measure amino acids,
plasma free amino acids (PFAAs), which abundantly circulate as a
medium linking all organ systems, would be the most favorable
target because their profiles have been known to be influenced by
metabolic variations in specific organ systems induced by specific
diseases [18,19,20,21]. Additionally, plasma samples can be
collected easily from patients.
Several investigators have also reported changes in PFAA
profiles in cancer patients [22,23,24,25,26,27,28]. However,
despite evidence of a relationship between PFAA profiles and
some types of cancer, few studies have explored the use of PFAA
profiles for diagnosis because, although PFAA profiles differ
significantly between patients, the differences in individual amino
acids do not always provide sufficient discrimination abilities by
themselves [24,29,30]. To address this issue, we previously
constructed and tested a diagnostic index based on PFAA
concentrations, known as the ‘‘AminoIndex technology’’
[29,30,31,32,33], to compress multidimensional information from
PFAA profiles into single dimension and maximize the differences
between patients and controls (Figure 1). We obtained preliminary
data on the efficacy of the ‘‘AminoIndex technology’’ for the early
detection of colorectal, breast, and lung cancers in approximately
150 samples from a single medical institute [29,30].
Moreover, technologies have recently been developed to
analyze amino acids with high accuracy. For example, we
developed a method to measure PFAA profiles using high-
performance liquid chromatography (HPLC)–electrospray ioniza-
tion (ESI)–mass spectrometry (MS) [34,35,36].
The present study aimed to determine the possibility of PFAA
profiling for cancer diagnosis using a large number of samples
from multiple medical institutes. We measured the PFAA profiles
of approximately 200 cancer patients from three different institutes
each with one of the following five types of cancer: lung, gastric,
colorectal (CRC), breast, or prostate cancer. Patients were
compared to five times sizes of gender- and age-matched controls
also used in this study. We then compared the alterations in the
Figure 1. Concept of the generation of ‘‘AminoIndex technology’’. At the top of the diagram, PFAA concentrations are measured for each
subject. In the middle, target variables and univariate analysis of PFAA profiles are represented. At the bottom, an estimation of the classifier with
optimized discriminating power using multivariate analysis is presented.
doi:10.1371/journal.pone.0024143.g001
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univariate and multivariate analyses. As a result, significant
alterations in PFAA profiles were observed in cancer patients in
comparison to control subjects. We demonstrated two types of
alterations in PFAA profiles in cancer patients: some differences
reflected the metabolic changes common to many cancers, while
others were specific to each type of cancer. We also found that
both common and cancer type-specific alterations in PFAA
profiles were observed even in the patients with early stage
cancer. Furthermore, using a large number of samples allowed us
to verify the robustness of PFAA profiling for the early detection of
various cancers.
Materials and Methods
Ethics
The study was conducted in accordance with the Declaration of
Helsinki, and the protocol was approved by the ethics committees
of the Kanagawa Cancer Center, the Osaka Medical Center for
Cancer and Cardiovascular Diseases, the Okayama University
Hospital, the Yokohama City University Medical Center, the
Gunma Prefectural Cancer Center, the Shizuoka Prefectural
Cancer Center, the Chiba Prefectural Cancer Center, the
Yokohama Municipal Citizen’s Hospital, the Yokohama Minami
Kyosai Hospital, the Kanagawa Health Service Association, the
Kameda Medical Center Makuhari, and the Mitsui Memorial
Hospital. All subjects gave their written informed consent for
inclusion before they participated in the study. All data were
analyzed anonymously throughout the study.
Subjects
Data from Japanese patients with lung cancer (LC), gastric
cancer (GC), colorectal cancer (CRC), breast cancer (BC), and
prostate cancer (PC) were analyzed in this study. The patients had
been histologically diagnosed with primary cancer at various
Japanese medical institutes between 2006 and 2009. The LC
patients were recruited from the Osaka Medical Center for Cancer
and Cardiovascular Diseases, the Chiba Prefectural Cancer
Center, the Kanagawa Cancer Center, and the Gunma Prefec-
tural Cancer Center. The GC patients were recruited from the
Okayama University Hospital, the Gunma Prefectural Cancer
Center, and the Shizuoka Prefectural Cancer Center. The CRC
patients were recruited from the Kanagawa Cancer Center, the
Shizuoka Prefectural Cancer Center, and the Gunma Prefectural
Cancer Center. The BC patients were recruited from the
Yokohama City University Medical Center, the Kanagawa
Cancer Center, and the Gunma Prefectural Cancer Center. The
PC patients were recruited from the Kanagawa Cancer Center,
the Yokohama Municipal Citizen’s Hospital, the Yokohama
Minami Kyosai Hospital, and the Gunma Prefectural Cancer
Center. Control subjects with no apparent cancer were chosen
from among those undergoing comprehensive medical examina-
tions at three different Japanese medical institutes (the Center for
Multiphasic Health Testing and Services of the Mitsui Memorial
Hospital, the Kameda Medical Center Makuhari, and the
Kanagawa Health Service Association) between 2008 and 2009.
Colonic polyp patients were recruited from among those
undergoing endoscopic polypectomy at the Kameda Medical
Center Makuhari between 2006 and 2008.
For the purposes of data analysis, the patients were assigned to
five groups based on their primary cancer diagnoses (,140–200
patients per group), and five age- and gender-matched control
groups were also established (Table 1). Data sets for all of the
cancer patients and controls, as well as all cancer patients stratified
by gender, were also analyzed.
PFAA measurement
Blood samples were collected from the controls and the patients
prior to any medical treatment. Blood samples (5 ml) were
collected from forearm veins after overnight fasting in tubes
containing ethylenediaminetetraacetic acid (EDTA; Termo, To-
kyo, Japan) and were immediately placed on ice. Plasma was
prepared by centrifugation at 3,000 rpm at 4uC for 15 min and
then stored at 280uC until analysis. After the plasma collection, all
samples were stored and processed at the Institute for Innovation
of the Ajinomoto Co., Inc. (Kawasaki, Japan). To reduce any bias
Table 1. Demographic and clinical characteristics of subjects.
Data set LC GC CRC BC PC
Patients Controls Patients Controls Patients Controls Patients Controls Patients Controls
Size Total 200 996 199 985 199 995 196 976 134 666
M/F 125/75 635/371 126/73 626/359 114/85 570/425 0/196 0/976 134/0 666/0
Age Mean 65.0
a 63.2 64.8
a 62.9 63.7 62.4 55.3 54.5 69.4
c 65.8
(SD) (10.0) (9.2) (10.8) (9.7) (9.5) (9.5) (12.6) (11.1) (6.7) (6.1)
BMI Mean 22.5 22.9 22.7 22.8 23.0 22.8 22.4 22.0 23.4 23.4
(SD) (3.8) (3.0) (3.2) (3.0) (3.7) (3.0) (3.4) (3.5) (2.7) (2.5)
Stage 0 - - 8 26 - -
I(A) 29 120 63 75 0
II(B) 16 29 48 73 95
III(C) 54 26 59 13 19
IV(D) 28 24 19 0 15
Uncharacterized 1 0 2 9 5
ap,0.05,
cp,0.001.
For LC, GC, CRC, and BC, cancer stages were determined according to the International Union Against Cancer TNM Classification of Malignant Tumors, 6th edition [38],
and for PC, cancer stages were determined according to Jewett staging system [39].
doi:10.1371/journal.pone.0024143.t001
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order. The plasma samples were deproteinized using acetonitrile
at a final concentration of 80% before measurement. The amino-
acid concentrations in the plasma were measured by HPLC–ESI–
MS, followed by precolumn derivatization. The analytical
methods used were as described previously [34,35,36].
Among the 20 genetically-encoded amino acids, glutamate
(Glu), aspartate (Asp), and cysteine (Cys) were excluded from the
analysis because they are unstable in blood. Citrulline (Cit) and
ornithine (Orn) were measured instead because they are relatively
abundant in blood and are known to play important roles in
metabolism. The following 19 amino acids and related molecules
were therefore measured and analyzed: alanine (Ala), arginine
(Arg), asparagine (Asn), Cit, glutamine (Gln), glycine (Gly),
histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys),
methionine (Met), Orn, phenylalanine (Phe), proline (Pro), serine
(Ser), threonine (Thr), tryptophan (Trp), tyrosine (Tyr), and valine
(Val).
Two metrics were made for each of the 19 amino acids
including the absolute concentration of each amino acid, which
directly reflected its availability and consumption, and the ratios
associated with the specific metabolic status in each organ. The
concentrations of the amino acids in the plasma were expressed in
mM, and the ratios of the amino acid concentrations were
expressed by the follow equation:
X2i,j~
Xi,j X
k
Xi,k
where X2i,j is ratio of the amino-acid concentration of the j-th
amino acid of i-th subject, and Xi,j is the plasma concentration
(mM) of the j-th amino acid of i-th subject.
Statistical analysis
Two types of metric were used for each data set for analysis
using either the amino-acid concentration or the ratio as
explanatory variables.
Mean and SD. The mean amino-acid concentrations 6
standard deviations (SDs) were calculated to determine
summarized PFAA profiles for both patients and controls.
Mann-Whitney U-test. The Mann-Whitney U-test was used
to assess significant differences of the plasma amino-acid
concentrations between the patients and the controls.
ROC analysis. Receiver-operator characteristic (ROC) curve
analyses were performed to determine the abilities of uni- and
multi-variate analyses to discriminate between patients and
controls. The patient labels were fixed as positive class labels.
Therefore, an area under the ROC curve (AUC of ROC) value of
,0.5 indicated that the amino acid level was lower in the patients
than the controls, whereas an AUC of ROC value of .0.5
indicated that it was higher. The 95% confidence interval (95%
CI) of AUC of ROC for the discrimination of patients based on
amino acid concentrations and ratios was also estimated as
described by Hanley and McNeil [37].
Two-way analysis of variance (ANOVA). The two-way
ANOVA was used to evaluate the effects of gender, age, and
smoking status as potential confounding factors. The presence of
cancer and gender were assumed to be independent factors, age
was treated as a continuous predictor rather than a categorical
predictor, and the interaction term between the presence of cancer
and smoking status was analyzed.
Two-class linear discrimination analysis (LDA). Linear
discrimination analysis (LDA) with stepwise variable selection was
performed to distinguish patients with each type of cancer from
the control subjects, in which both the maximum and the
minimum p-values for a term to be added or removed were set at
0.001.
Multi-class LDA for discrimination. LDA with stepwise
variable selection was also performed to distinguish patients with a
specific cancer from the complete data set containing all cancer
patients stratified by gender (four kinds of cancer patients in each
data set). Because the size of each group was smaller than that of
two-class LDA, the maximum p-value for a term to be added was
set at 0.05 and the minimum p-value for a term to be removed was
set at 0.10. The Mahalanobis distance was used as a metric of
classification. The accuracy was defined as the ratio of the
correctly discriminated patients to the total number of patients
with each cancer instead of AUC of ROC because ROC analysis
could be applied only for two-class discrimination.
Leave one out cross—validation (LOOCV). LOOCV was
performed to correct potential over-optimization for obtained
LDA models. Briefly, one sample was omitted from the study data
set, and the LDA model was calculated for the remaining samples
to estimate coefficients for each amino acid. The function values
for the left-out sample were calculated based on the model. This
process was repeated until every sample in the study data set had
been left out once.
Conditional logistic-regression (c-logistic) analysis. C-
logistic analysis was also performed to verify the effects of age and
gender, potential confounding factors, on the discriminatory
abilities of obtained LDA models to differentiate patients with
each type of cancer from the controls.
Subgroup analysis. To assess the effects of cancer stage,
each data set was divided into a sub-data set according to disease
stage and including corresponding controls, and analyzed using
the ROC analysis in each data set.
Software
MATLAB (The Mathworks, Natick, MA) was used for the
calculations of mean and SD, the Mann-Whitney U-test, ROC
analysis, two-way ANOVA, LDAs, and LOOCV. GraphPad
Prism (GraphPad Software, La Jolla, CA) was also used for the
ROC curve analysis. LogXact (Cytel, Cambridge, MA) was used
for the c-logistic analysis.
Results
Characteristics of subjects
Table 1 summarizes the characteristics of the subjects in this
study. The data sets comprised 200 LC patients and 996 controls,
199 GC patients and 985 controls, 199 CRC patients and 995
controls, 198 BC patients and 976 controls, and 134 PC patients
and 666 controls (Table 1). The sample size for each cancer type
was greater than those in previous reports [25] and provided
sufficient statistical power to test the robustness of the PFAA
profiles for cancer diagnosis.
There were no significant differences in body mass index (BMI)
among the data sets (Table 1). Weight loss due to malnutrition was
therefore not expected to influence the results. Although
significant differences in average age were observed among the
data sets (LC, p,0.05; GC, p,0.05; and PC, p,0.001), the effects
appeared to be relatively minor because the absolute values of
these differences were small (Table 1).
For LC, GC, CRC, and BC, disease stages were determined
according to the Sixth Edition of the International Union Against
Cancer (UICC) Tumor–Node–Metastasis (TNM) Classification of
Malignant Tumors [38]. For PC, the stage was determined
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a large proportion of the patients had early-stage disease. The
fractions of patients at each stage according to type of cancer were
as follows: ,50% stage I, ,10% stage II, ,25% stage III, and
,15% stage IV for LC; ,60% stage I, ,15% stage II, ,13%
stage III, and ,12% stage IV for GC; ,35% stages 0 and I,
,25% stage II, ,30% stage IV, and ,10% stage IV for CRC;
,5% stage 0, ,25% stage I, ,25% stage II, and ,7% stage III
for BC; and ,75% stage B, ,13% stage C, and ,12% stage D for
PC (Table 1).
The patients with each type of cancer could be further
subdivided based on histological type (for LC, GC, CRC, and
BC) or Gleason score (for PC), as is summarized in Table S1. The
characteristics of 34 colonic polyp patients as well as the smoking
status of patients are also summarized in Table S1.
Shared PFAA profiles among cancers
Univariate analysis was used to compare the PFAA profiles of
the cancer patients and controls. The differences in the
significance levels of each amino acid between the patients and
the controls are shown in Figure 2A. The results of the ROC
analysis are depicted in Figure 2B because the levels of significance
depend on sample size. The concentrations and ratios of each
amino acid profile for both patients and controls are shown in
Tables S2. And the AUCs of ROC and their CIs of each amino
acid are shown in Table S3 (concentration) and Table S4 (ratio),
respectively.
Two-way ANOVA was used to evaluate the potential
confounding effects of gender, age, and smoking status. Correcting
for these factors did not greatly affect the significance levels of each
amino acid, suggesting that their effects on the PFAA profiles were
minor (Table S5).
The plasma concentrations of Gln, Trp, and His were
significantly decreased in all of the cancers except PC, and none
of the amino acids showed increased concentrations across all
types of cancer (p,0.05). The ratios of Trp and His were
significantly decreased, while those of Pro and Orn were
increased, in all cancers (p,0.05) (Figure 2).
To further examine the shared traits among cancer patients, the
PFAA profiles were compared using a pooled data set including all
cancer patients and controls. Notably, the amino acids that were
affected by this type of analysis had significant differences in both
concentration and ratio: 11 amino acids (Asn, Gln, Cit, Val, Met,
Leu, Tyr, Phe, His, Trp, and Arg) showed decreases, while four
amino acids (Ser, Pro, Gly, and Orn) exhibited increases (Figure 2).
Changes in Gln, Trp, His, Pro, and Orn were detected in the
analysis for all types of cancer. Alterations in these amino acids
might therefore reflect characteristic changes in metabolism that
are common to all cancers.
Specific PFAA profiles for each cancer
In addition to the changes that were common to all of the
cancers, we detected alterations in PFAA profiles that were specific
to each disease type (Figure 2). Overall, the concentrations of most
amino acids were decreased in GC and CRC patients, whereas no
clear trends in amino acid concentrations were observed in the
other groups (Figure 2). Furthermore, some of the amino acids
showed opposite trends in different types of cancer. For example,
the concentrations of Thr were decreased in GC and CRC
patients, but increased in BC patients (Figure 2). These variations
in the PFAA profiles might reflect specific characteristics of each
cancer, in contrast to the limited set of amino acids that are
responsible for the metabolic changes shared by all cancers.
Changes in PFAA profiles in early-stage cancers
Although alterations in the PFAA profiles of cachexic patients
with advanced cancer have been well documented, few reports
have considered early-stage patients. However, a large fraction of
the cancer patients in the current data set were in the early stages
of disease (Table 1). The differences in PFAA profiles according to
disease stage were therefore examined for each cancer (Figure 3,
Figure S1, Table S3, Table S4).
Notably, alterations in the PFAA profiles were detected in all
patients, including those in the early stages of disease, in the
current study. All amino-acid concentrations and ratios were
drastically decreased in early stage disease patients, regardless of
the subsequent progression. In particular, significant decreases of
each amino acid concentration were observed in GC and CRC
patients (Figure 3A), and changes in each ratio were notable in all
of the cancer patients (Figure 3B).
Early-stage cancer patients are generally asymptomatic. More-
over, most of the subjects in the present study did not show
significant weight loss (a symptom typical of cachectic patients)
(Table 1), anorexia, or decreases in serum albumin concentrations
(data not shown). The changes in the PFAA profiles in cancer
patients therefore appeared to be independent of any effects
caused by poor nutrition resulting from tumor progression.
Discriminating cancer patients and controls by PFAA
profiles
The results of the univariate analyses suggested that cancer
patients and controls could be discriminated using multivariate
analysis. By assuming that the presence of cancer and the
concentrations or ratios of the PFAA profiles were objective and
explanatory variables, respectively, LDA was able to distinguish
cancer patients from the corresponding controls with variable
selection. The results of variable selection are indicated in Table 2
(concentration) and Table S6 (ratio), respectively.
The discrimination abilities for each cancer patient were
evaluated using the AUC of ROC of the discriminate score and
were found to be .0.75 in all cases (Table 3 and Table S7). In
concrete analysis, AUCs for the discrimination of patients based
on the amino acid concentrations and ratios, respectively, were
also estimated as follows: 0.802 (95% CI: 0.766,0.838) and 0.802
(95% CI: 0.767,0.837) for LC; 0.849 (95% CI: 0.816,0.882) and
0.816 (95% CI: 0.780,0.852) for GC; 0.874 (95% CI:
0.842,0.906) and 0.881 (95% CI: 0.851,0.910) for CRC;
0.778 (95% CI: 0.741,0.815) and 0.778 (95% CI:
0.741,0.815) for BC; and 0.783 (95% CI: 0.740,0.826) and
0.779 (95% CI: 0.740,0.819) for PC (Table 3 and Table S7). The
discriminate analysis was therefore able to adequately distinguish
between different types of patient cancer.
Variable selection was also performed for each cancer patient.
Eight amino acids were selected in more than two of the five kinds
of cancers: Gln, Ala, Val, Ile, His, Trp, Orn, and Lys for the
concentrations (Table 2A); and Ser, Gln, Val, Met, His, Trp, Lys,
and Arg for the ratios (Table S6). Four of the amino acids (Gln,
Val, His, and Trp) among each set were selected for both
explanatory variables (Table 2 and Table S6). These amino acids
were similar to those associated with all types of cancer as
indicated by the univariate analysis (Gln, Trp, His, Pro, and Orn).
On the other hand, some amino acids incorporated into the LDA
model were not identified as significant amino acids by the univariate
analysis. For example, the Val concentration did not show a
significant alteration in the univariate analysis (Figure 2A), but it was
incorporated into the LDA model (Table 2). Because plasma
concentrations of each amino acid are metabolically connected to
each other, there might be a potential correlation that cannot be
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correlation coefficient between Val and cancer (or not) was 20.127
(p,0.001), while the correlation coefficient between these two factors
was0.035(notsignificant).Therefore,thissuggestedthattheobtained
LDA model reflected the metabolic network of PFAAs, which were
not apparent thorough univariate analysis.
Because the obtained results may have been over-optimized,
LOOCV was carried out to generate an unbiased analysis. This
produced AUCs similar to those obtained for LDA, suggesting that
there was no obvious over-optimization in the obtained LDA
models (Table 3 and Table S7).
Subgroup analyses of divided data sets according to cancer stage,
including corresponding controls, were then performed to assess the
ability of PFAA profiles to distinguish between stages of cancer for
each type of disease. In any stage of each cancer, the AUC of ROC
was found to be higher than 0.75, suggesting that the obtained LDA
models would thus be expected to be effective in detecting early as
well as advanced stage cancers (Table 3 and Table S7).
The discrimination abilities for all cancer patients were also
evaluated. The AUCs of ROC for both concentrations and ratios
were 0.796 (95% CI: 0.779,0.814) and 0.785 (95% CI:
0.767,0.803), respectively (Table 3 and Table S7). Notably, most
of the 19 amino acids were statistically selected for these
discriminations: 16 for the concentrations and 12 for the ratios.
Even using a rough classification, regardless of the type of cancer,
it was possible to discriminate between patients and controls with
high accuracy, and the overall contributions of numerous amino
acids might reflect the large-scale characteristic changes associated
with cancer metabolism.
A c-logistic analysis using matching factors (gender and age) was
performed for each data set to evaluate and correct for potential
confounding factors. Note that we used the combinations of amino
acids obtained from the LDA models as explanatory variables.
Although the c-logistic analysis was performed using all of the
significant variables identified by the univariate analysis, the amino
acids identified in the LDA were utilized to correct for potential
confounding factors more adequately (data not shown). Both the
levels of significance (Table 2 and Table S6) and the discrimina-
tion abilities (Table 3 and Table S7) were not significantly altered
by correcting for the potentially confounding factors, suggesting
that these results were independent of gender and age effects.
To evaluate patients with non-neoplastic diseases, the PFAA
profiles of colonic polyp patients were substituted into the LDA
model for CRC. Most of the colonic polyp patients (31/34, 91.2%)
were classified into the control group for the concentrations and
ratios of both models, suggesting that the obtained models could
discriminate CRC patients specifically.
Discrimination between cancer types by PFAA profiles
In addition to differentiating between patients with each type of
cancer and the controls, discrimination among patients within
each cancer group was also performed by separating all the cancer
patients into each disease subtype according to gender. This was
done because the results of the present analyses identified changes
in PFAA profiles that were common to all types of cancer as well as
those specific to individual cancers.
The accuracies of all discriminant analyses using amino acid
concentrations as explanatory variables were close to or better than
50% both in male patients (Table 4) and female patients (Table 5)
data set. The discrimination accuracy among cancer patients was
less than that between patients and controls. Six amino acids (Gly,
Cit, Val, Tyr, Trp, and Arg) were commonly selected in these
analyses, regardless of gender (data not shown). An additional six
amino acids (Gln, Met, Leu, His, Orn, and Lys) were selected in the
male patient data set, and four (Thr, Ser, Ile, and Phe) were selected
in the female patient data set (data not shown). Five of the 16 amino
acids listed above were selected in the discrimination between
patients and controls, while the remainder might have been
responsible for the characteristic features of each cancer.
The accuracies were similar between the analyses using ratios as
explanatory variables and those using concentrations both in male
patients (Table S8) and female patients (Table S9). Seven amino
acids (Gln, Cit, Val, Tyr, Trp, Lys, and Arg) were commonly
selected regardless of gender in these analyses (data not shown). An
additional four amino acids (Ala, Met, Leu, and His) were selected
in the male patient data set, and four (Thr, Ser, Ile, Orn) were
selected in the female patient data set (data not shown). Five amino
acids (Cit, Val, Tyr, Trp, and Arg) from each set were selected for
both explanatory variables, suggesting that the changes to the
respective PFAAs were specific to certain types of cancer.
LOOCV was also carried out and resulted in similar accuracies
for the discrimination analyses, suggesting that there was no
obvious over-optimization in the obtained models (Table 4,
Table 5, Table S8 and Table S9).
Discussion
The present study demonstrated the use of PFAA profiling as a
focused metabolomics approach for the early detection of patients
with any of five types of cancer. Combining novel analytical
techniques and both univariate and multivariate statistical
analyses, previously unknown aspects of amino acid metabolism
in humans have been revealed. The sample size in the present
study was considerably larger than those reported previously
[25,29,30], and provided sufficient statistical power to test the
robustness of PFAA profiling for cancer diagnosis. We also
demonstrated the possibility of detecting cancers, both specifically
and broadly, using multivariate analysis to compress the PFAA
profile data, even for patients with early stage cancer.
In the previous studies, the alterations in PFAA profiles in cancer
patients sometimes seem inconsistent[22,23,24,25,26,27,28,29,30],
and some discrepancies existed between ourcurrentstudy and those
reported in the literature [25]. This discrepancy may be due not
only to sample size and the varying predominance of early stage
cancers but also to some other factors such as amino acid
measurement methods. On the other hand, alterations in the PFAA
profiles in our present study were consistent with the results of our
previous studies, in which samples were collected from a single
medical institute [29,30]. Furthermore, there are also many
similarities between our results and those of previous studies. For
example,decreasesinHis and Glnlevels, whichhave beenobserved
broadly in previous reports, and increases in Pro and Ala levels in
BC are consistent with our findings [25].
Figure 2. PFAA profiles of cancer patients. The results of the Mann-Whitney U-test (A) and receiver-operator characteristic (ROC) curve analysis
(B) are indicated. A. Colored cells indicate that the concentration or ratio is increased in cancer patients at p,0.001 (red), p,0.01 (orange), and
p,0.05 (pink), and decreased in cancer patients at p,0.001 (blue), p,0.01(sky blue), and p,0.05 (light blue), respectively. B. Axes show the AUC of
ROC for each amino acid to discriminate patients from controls. Concentrations and ratios of each cancer patient and the pooled data set are
indicated, respectively. Black bold lines indicate the point where the AUC of ROC=0.5.
doi:10.1371/journal.pone.0024143.g002
Plasma Amino Acid Profiles of Cancer Patients
PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24143Plasma Amino Acid Profiles of Cancer Patients
PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e24143Cancer is expected to become the leading cause of death
worldwide within a few years. Therefore, it is crucial that methods
for the prevention, early detection, and treatment of cancers
should be implemented to reduce mortality. Various screening
methods have been established for the cancers included in our
study. However, the high specificity of these methods means that
subjects must undergo each screening examination separately,
which can be expensive and time consuming. These examinations
can also impose a physical and/or mental burden upon subjects,
which can lead to avoidance. By contrast, the method described in
the present study involves a relatively simple plasma assay and
imposes a low physical burden on subjects. This method could also
be used as versatile health assessment as other diseases in which
PFAA profiles can be altered, such as diabetes[18], hepatic
failure[19], and renal failure[21], can also be evaluated.
It should be noted that the models derived from this case-control
study could not be used directly to make further observations or
predictions, despite providing a preliminary demonstration of the
potentially high value of this method for cancer discrimination.
Further investigations, including model construction and validation
using cohorts with larger sample sizes, are in progress to clarify the
clinical utility of this approach. Moreover, the possibility of
continuous PFAA profiling as a means to determine prognosis after
surgery or chemotherapy is also being investigated.
Our investigation demonstrated two types of alterations in PFAA
profiles of cancer patients: those in a limited set of amino acids
reflectingmetabolic changescommontomanycancers;andthosein
a larger group of amino acids representing metabolic characteristics
specific to each cancer. Alterations in PFAA profiles were observed
even in patients with early-stage cancer, most of whom had no
apparent symptoms. This strongly suggested that the alterations in
PFAA profiles identified in the current study were independent of
the effects of poor nutrition caused by tumor progression.
Many previous reports have shown that metabolism, including that
of amino acids, is notably altered in cancer cells [3,13,40] and that
changes in PFAA profiles can also occur [22,24,25,26,27,28,29,30],
especially in cachexic patients with advanced cancer [23,25]. Among
whole metabolites, amino acids have been frequently identified as
having associations with cancer in other studies [10,13,41,42,43].
The current study demonstrated that mechanisms other than
malnutrition can drive the changes in PFAA profiles.
Besides cancer-dependent malnutrition, significant decreases in
PFAA concentrations and various indicators of nutritional status
such as BMI and serum albumin levels are observed in cancer-
independent cachexia [44,45,46]. In the present study, no
apparent decreases in those indicators were observed, strongly
suggesting that alterations in PFAA were also independent of
nutritional status mediated by factors not related to cancer.
Figure 3. PFAA profiles of early- and advanced-stage cancer patients. The axes show the AUC of ROC for each amino acid for discriminating
patients from controls. A. Comparison of concentrations of cancer patients and controls. B. Comparison of ratios of cancer patients and controls. Scale
as described for Figure 2. For LC, GC, CRC, and BC, cancer stages were determined according to the International Union Against Cancer TNM
Classification of Malignant Tumors, 6th edition [38], and for PC, cancer stages were determined according to Jewett staging system [39].
doi:10.1371/journal.pone.0024143.g003
Table 2. Variables incorporated into LDA and c-logistic models using concentrations as explanatory variables.
Amino acid LC GC CRC BC PC Pooled
LDA C-logit LDA C-logit LDA C-logit LDA C-logit LDA C-logit LDA C-logit
Thr +++ +++ +++ +++
Ser +++ +++ +++ +++ +++ +++
Asn
Gln 222 222 222 222 222 222 222 222
Pro +++ +++ +++ +++
Gly +++ ++
Ala +++ +++ +++ +++ +++ +++ +++ +++
Cit 222 222 222 2 222
Val 222 2 222 22 222 222 222 222 222 222
Met 222 222
Ile +++ +++ +++ + +++ +++ +++ ++ +++ +++
Leu +++ +++ +++ ++
Tyr 222 222 222 22
Phe +++ +++ +++ +++
His 222 222 222 222 222 222 222 222
Trp 222 222 222 222 222 22 222 222 222 222 222 222
Orn +++ +++ +++ +++ +++ +++ +++ +++
Lys +++ +++ +++ +++ +++ +++ +++ +++
Arg 222 222 222 222 222 222
+, ++, +++: positive coefficients in the model.
2, 22, 222: negative coefficients in the model.
+,2:p ,0.05, ++,22:p ,0.01, +++,222:p ,0.001.
doi:10.1371/journal.pone.0024143.t002
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occurring in cancer patients affect the PFAA profile of the whole
body, even in patients with early-stage tumors. To clarify the
relationship between carcinogenesis and changes in PFAA profiles,
we are further investigating the contribution of local effects caused
by cancer cell metabolism and the systemic responses of the
immune system against tumors or factors released by cancer cells.
Changes in metabolism can be detected in cancer cells even in
early-stage patients. Hirayama et al. reported no significant
correlation between the levels of cancer cell metabolites, including
several amino acids, and the tumor stage [13]. The metabolism of
Trp is of particular interest because it was identified as one of the
most important amino acids in relation to cancer progression in
our study. Overexpression of indoleamine-2,3- dioxygenase (IDO),
the first enzyme in the kynurenine Trp metabolism pathway in
humans, has been reported in cancer cells [47]. IDO is induced in
many different tumors and has been suggested to play a role in
cancer-mediated evasion of the immune system [47,48,49,50].
Arg, Orn, Cit, and Pro are known to be closely related to
immune function. For example, Qiu et al. reported an association
between the urea cycle and metabolic alterations in CRC patients
and found no correlation between the metabolite profile and
cancer progression [43]. Cancer cells also release factors that can
alter general physical conditions. For example, the transcriptional
regulatory molecule high-mobility group B1 (HMGB1) was
recently shown to regulate cancer-cell tumorigenesis, expansion,
and invasion [51,52,53].
Further elucidation of these mechanisms might allow for the
development of both static and dynamic models of carcinogenesis
through system analysis [31]. Recently, computer-aided studies
have been reported that integrate hierarchical ‘omics’ datasets for
the systemic understanding of metabolic phenotypes to reconstruct
the regulatory network from physiological data by means of system
analysis. System analysis of cancer patients based on whole body
amino acid metabolism could reveal information concerning the
nature of a disease and help to establish strategies for its
prevention, early detection, prognosis, monitoring, and treatment.
In contrast to many similar efforts to detect biomarkers of
disease as single specific molecules (DNA, microRNA, proteins,
peptides, or metabolites) in peripheral blood, our approach was to
focus on the metabolic status, which is indicative of multivariate
function, using non-specific metabolites. Therefore, we believe
that our method is superior to those used in other studies, both in
versatility and efficiency, because only one amino acid measure-
ment can be applied for detection of various disease states (i.e.,
renal failure, hepatic failure, and nutritional status).
Table 3. Discrimination performance of LDA and c-logistic models using concentrations as explanatory variables.
Model Subjects LC GC CRC BC PC Pooled
LDA All AUC 0.802 0.849 0.874 0.778 0.783 0.796
CI (0.766,0.836) (0.816,0.882) (0.842,0.906) (0.741,0.815) (0.740,0.826) (0.779,0.814)
LOOCV AUC 0.792 0.845 0.868 0.769 0.767 0.793
Stage 0 patients AUC - - 0.903 0.813
CI (0.807,1.00) (0.726,0.900)
Stage I patients AUC 0.752 0.859 0.859 0.754
CI (0.698,0.805) (0.820,0.898) (0.800,0.918) (0.692,0.817)
Stage II(B) patients AUC 0.870 0.829 0.921 0.786 0.764
CI (0.772,0.969) (0.726,0.933) (0.877,0.954) (0.727,0.847) (0.710,0.819)
Stage III(C) patients AUC 0.844 0.834 0.817 0.755 0.777
CI (0.780,0.908) (0.748,0.920) (0.743,0.892) (0.621,0.889) (0.669,0.885)
Stage IV(D) patients AUC 0.901 0.843 0.950 - 0.873
CI (0.837,0.966) (0.734,0.951) (0.895,1.00) (0.771,0.974)
C-logit All AUC 0.806 0.850 0.876 0.776 0.786 0.798
CI (0.771,0.841) (0.816,0.883) (0.845,0.907) (0.739,0.812) (0.743,0.829) (0.780,0.815)
doi:10.1371/journal.pone.0024143.t003
Table 4. Multiclass discriminant analyses of male cancer patients using concentrations as explanatory variables.
Patients with:
LC GC CRC PC
Discriminated as: LC 72(69) 19(22) 12(13) 26(26)
GC 18(19) 58(52) 16(17) 25(25)
CRC 13(14) 25(28) 71(69) 16(17)
PC 22(23) 24(24) 15(15) 67(66)
Total 125 126 114 134
Accuracy 57.6%(55.2%) 46.0%(41.3%) 62.3%(60.5%) 50.0%(49.3%)
The numbers in the blanket indicate the results of LOOCV.
doi:10.1371/journal.pone.0024143.t004
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Figure S1 PFAA profiles of cancer patients stratified by
progression stage. The axes show the AUC of ROC for each
amino acid for discriminating patie n t sf r o mc o n t r o l s .A .C o m p a r i s o n
of concentrations of cancer patients and controls. B. Comparison of
ratios of cancer patients and controls. Scale as described for Figure 2.
For LC,GC, CRC,and BC,cancerstageswere determined according
to the International Union Against Cancer TNM Classification of
Malignant Tumors, 6th edition [38], and for PC, cancer stages were
determined according to Jewett staging system [39].
(TIF)
Table S1 Detailed demographic and clinical character-
istics of subjects. a: p,0.05, c: p,0.001 *: For LC, GC, CRC,
and BC, cancer stages were determined according to the
International Union Against Cancer TNM Classification of
Malignant Tumors, 6th edition [38], and for PC, cancer stages
were determined according to Jewett staging system [39].
(XLS)
Table S2 PFAA profiles of cancer patients and controls.
(XLS)
Table S3 AUCs of ROC of each amino acid concentra-
tion for discrimination for cancer patients from con-
trols.
(XLS)
Table S4 AUCs of ROC of each amino acid ratio for
discrimination for cancer patients from controls. AUCs
were calculated using all patients and controls, and patiens and
matched controls stratified by cancer stage.
(XLS)
Table S5 Significance values for PFAA profiles for each
data set by two-way ANOVA for the effects of cancer
existence and other parameters. Column headings indicate
Mann-Whitney U-test of cancer existence (None), two-way
ANOVA for the effects of cancer existence and gender (Gender),
cancer existence and age (Age), and cancer existence and smoking
status (Smoking).
(XLS)
Table S6 Variables incorporated into LDA and c-
logistic models using ratios as explanatory variables.
+, ++, +++: positive coefficients in the model 2, 22, 222:
negative coefficients in the model +,2:p ,0.05, ++,22:p ,0.01,
+++,222:p ,0.001.
(XLS)
Table S7 Discrimination performance of LDA and
c-logistic models using ratios as explanatory variables.
(XLS)
Table S8 Multiclass discriminant analyses of male
cancer patients using ratios as explanatory variables.
The numbers in the blanket indicate the results of LOOCV.
(XLS)
Table S9 Multiclass discriminant analyses of female
cancer patients using ratios as explanatory variables.
The numbers in the blanket indicate the results of LOOCV.
(XLS)
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